Bass and Spangenberg double down on IPR strategy

Hedge fund manager Kyle Bass and IP Nav’s Erich Spangenberg have filed a second inter partes review petition against a patent owned by Acorda Therapeutics, as part of a strategy BIO said had “opened a new door to abuse of the US patent system”